Trial Profile
A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects With Heart Failure and Left Ventricular Systolic Dysfunction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Omecamtiv mecarbil (Primary)
- Indications Chronic heart failure; Left ventricular dysfunction
- Focus Pharmacokinetics
- Acronyms COSMIC-HF
- Sponsors Amgen
- 29 Aug 2022 Results of meta-analysis of 4 trials (NCT02695420, COSMIC-HF, ATOMIC-AHF & GALACTIC-HF) assessing clinical outcomes of omecamtiv mecarbil in patients with Heart Failure with Reduced Ejection Fraction, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
- 05 Oct 2020 According to a Cytokinetics media release, data from this study was presented at the Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting 2020.
- 05 Oct 2020 Results published in the Cytokinetics media release